Can-Fite BioPharma up on positive data from psoriasis therapy study

Can Fite Biopharma

29/06/2022 18:18

** U.S.-listed shares of Israeli biotech co Can-Fite
BioPharma  CANF.N  rise 12.2% to $0.99
    ** Co reports positive data from late-stage study testing
safety and efficacy of its experimental psoriasis therapy
Piclidenoson  urn:newsml:reuters.com:*:nBw8s5F8a
    ** At week 16, patients receiving 3 mg dose of Piclidenoson
demonstrated statistically significant improvement when compared
with placebo, meeting the study's main goal
    ** Plaque psoriasis is an inflammatory skin disorder which
causes dry, itchy, raised skin patches covered with scales
    ** Piclidenoson is co's lead drug candidate; CANF is also
developing therapies for liver diseases and erectile dysfunction
    ** U.S. stock down ~23% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com;))